← All stocks

CytomX Therapeutics, Inc.

CTMX Net selling
CIK 0001501989 #2811 in the set updated 21 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$1.69M
$1.23M on a plan · $0.00 straight out of an exercise
Sold at will
$468.01K
4 of 6 sales
Net
−$1.69M
−$468.01K against sales at will

By person

7 insiders · 6 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
McCarthy Sean A.
CEO
$1.23M (2) scheduled
−$1.23M
2,066,813
$6.30M
+25.6%
BELVIN MARCIA
SVP, Chief Scientific Officer
$202.27K (1)
−$202.27K
300,760
$917.32K
+66.5%
Chu Yu-Waye
Chief Medical Officer
$136.68K (1)
−$136.68K
189,446
$577.81K
+621.7%
Ogden Christopher
Chief Financial Officer
$129.06K (2)
−$129.06K
295,324
$900.74K
+173.3%
ROWLAND LLOYD A
General Counsel
120,594
$367.81K
−7.8%
Carvajal Alejandra
Chief Legal Officer
100,000
$305.00K
Lester Rachael
Chief Business Officer
20,000
$61.00K

No percentages here. This company's share count has moved by a factor of 2.8 over the window, from 78,258,879 to 217,899,284 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
McCarthy Sean A.
17 Mar 2026
CEO
Sold on a plan
118,969
$6.42
$764.14K
McCarthy Sean A.
6 Nov 2025
CEO
Sold on a plan
101,793
$4.54
$461.91K

What was left out

Form 4 filings counted 25
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 0
Shares from compensation/vesting 555,000
History held since 28 Sep 2016